Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms

Journal of Pediatric Hematology/oncology
Akshay SharmaBrandon M Triplett

Abstract

Recurrent/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell-depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent/refractory or secondary leukemia. Clofarabine was well tolerated at a dose of 50 mg/m/d for 5 days in this regimen, with minimal treatment-related mortality in a heavily pretreated group of high-risk patients. All patients exhibited quick hematopoietic recovery, with median times to neutrophil and platelet engraftment being 11 and 16 days, respectively. Transient elevation of transaminases was the most common toxicity-observed in 13 patients (86.7%), with 6 (40%) grade III or above. Three patients (20%) developed hepatic veno-occlusive disease. Eleven patients (73.3%) died, with the most common cause ...Continue Reading

References

Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BosiUNKNOWN Acute Leukemia Working Party of the European Blood and Marrow Transplant Group
Oct 4, 2006·Nature Reviews. Drug Discovery·Peter L BonateSteve Weitman
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Martha L ArellanoEdmund K Waller
Sep 25, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marco MielcarekPaul J Martin
Nov 6, 2009·Acta Haematologica·Maite HartwigUlrike Bacher
Jul 1, 2011·Journal of Pediatric Hematology/oncology·Lucas MorenoAmparo Verdeguer
Nov 15, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koen van BesienAndrew S Artz
Mar 1, 2012·Bone Marrow Transplantation·M KatoK Kato
Jul 11, 2013·Blood·Alan K BurnettUNKNOWN UK National Cancer Research Institute AML Working Group
Oct 1, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gita ThanarajasingamPhilippe Armand
Jun 20, 2014·European Journal of Clinical Investigation·Werner RabitschWolfgang R Sperr
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nelli BejanyanMei-Jie Zhang
Sep 15, 2015·Bone Marrow Transplantation·T RuutuUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
May 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Barbara SpitzerFarid Boulad

❮ Previous
Next ❯

Methods Mentioned

BETA
leukapheresis

Clinical Trials Mentioned

NCT00824135

Software Mentioned

CliniMACS
R Core
R

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.